LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/29/20

Collaboration initiates second Roche program utilizing Icagen’s ion channel drug discovery platform Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and c...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone pa...

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome Top-Line Data Expected in Q4 2020 from Phase 2/3 Pivotal Study for Fast Track-Designated...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this Read more ...

Previously, I wrote how investors need to be more selective in picking stocks because the SPDR S&P 500 Trust ETF ( SPY ) is approaching its 200-day moving average (DMA). If I've learned anything from helping professional money managers at mutual funds and hedge funds over the past 23 yea...

As expected , the market has moved from indiscriminate buying to stock picking. Following its rapid oversold rally, the SPDR S&P 500 ETF ( SPY ) has made little headway over the past month. Instead, investors have begun separating long-term winners from losers, resulting in significant ou...

Image source: The Motley Fool. Ligand Pharmaceuticals Inc   (NASDAQ: LGND) Q1 2020 Earnings Call May 6, 2020 , 4:30 p.m. ET Operator Continue reading

Ligand Pharmaceuticals Incorporated (LGND) Q1 2020 Results Earnings Conference Call May 06, 2020, 04:30 PM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance and Chief Financial Of...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2020 Q1 earnings Read more ...

Ligand Pharmaceuticals (NASDAQ: LGND ): Q1 Non-GAAP EPS of $0.89 beats by $0.23 ; GAAP EPS of -$1.46 misses by $1.58 . Revenue of $33.16M (-23.7% Y/Y) beats by $6.46M . Press Release More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks...